SCHEMBL15034049

SCHEMBL15034049

CC1(C)CN(C(=O)c2cc(Cl)cc(C(F)(F)F)c2)CCN1C(=O)c1ncn(-c2cccc(Cl)c2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 3/20 0.42
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
CYP3A4 P08684 8/20 0.40
USP2 O75604 3/20 0.40
HSD17B10 Q99714 3/20 0.40
SLC6A7 Q99884 1/20 0.39
CYP2D6 P10635 4/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
HPGD P15428 2/20 0.38
HIF1A Q16665 2/20 0.38
ALDH1A1 P00352 1/20 0.38
ALOX15 P16050 1/20 0.38
MAPK1 P28482 1/20 0.38
TSHR P16473 5/20 0.37
CYP1A2 P05177 2/20 0.37
RORC P51449 1/20 0.36
RHOC P08134 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15034162 0.94 CYP3A4 (0.45) MAPTCYP3A4USP2HSD17B10CYP2D6
SCHEMBL15034035 0.92 MGLL (0.46) MGLLPOLBMAPTSMN1; SMN2HPGD
SCHEMBL15019972 0.89 SLC6A7 (0.43) MGLLSLC6A7SMN1; SMN2HPGDALDH1A1
SCHEMBL15034111 0.88 SLC6A7 (0.40) MGLLPOLBMAPTHSD17B10SLC6A7
SCHEMBL15034094 0.86 SLC6A7 (0.42) MGLLPOLBMAPTSLC6A7SMN1; SMN2
SCHEMBL15034112 0.86 MGLL (0.43) MGLLPOLBMAPTHSD17B10SLC6A7
SCHEMBL15034239 0.85 SMN1; SMN2 (0.49) MGLLCYP3A4USP2HSD17B10SLC6A7
SCHEMBL15020006 0.85 ALDH1A1 (0.44) POLBMAPTSLC6A7SMN1; SMN2HPGD
SCHEMBL15034033 0.85 MGLL (0.39) MGLLPOLBMAPTSLC6A7SMN1; SMN2
SCHEMBL15034170 0.85 MAPT (0.42) POLBMAPTHSD17B10SLC6A7SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158042-A1 NOVEL COMPOUNDS GRM5, GRIK5, GRM1 MGLL 2123/4885POLB 4052/4885MAPT 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.